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Recently identiﬁed interleukin-28 and -29 belong to a novel type III interferon (IFN) family, which could have distinct biological
properties from type I and II IFNs. Type I IFNs, IFN-α/β, have been clinically applied for treating a certain kind of malignancies
f o ro v e r3 0y e a r s ,b u taw i d er a n g eo ft h ea d v e r s ee ﬀects hampered the further clinical applications. Type III IFNs, IFN-λs, have
similar signaling pathways as IFN-α/β and inhibits proliferation of tumor cells through cell cycle arrest or apoptosis. Restricted
patterns of type III IFN receptor expression in contrast to ubiquitously expressed IFN-α/β receptors suggest that type III IFNs have
limited cytotoxicity to normal cells and can be a possible anticancer agent. In this paper, we summarize the current knowledge on
the IFN-λs-mediated tumor cell death and discuss the functional diﬀerence between type I and III IFNs.
1.Introduction
Interferons (IFNs) have been described as agents mediating
antiviral responses over the years; however, further investi-
gations are still required to clarify the biological properties
and the mechanisms responsible for the functions [1]. There
are 3 IFN families currently known, which have diﬀerent
receptor structures [2, 3]. Type I IFN family consists of IFN-
α and IFN-β in human and binds a common heterodimeric
receptor complex, composed of IFNAR1 and IFNAR2 [4].
Type II IFN comprises of IFN-γ, which is not homologous
to type I IFNs in the structure, and binds a diﬀerent receptor
complex, IFNGR1 and IFNGR2 [2, 3]. The interaction of
type I IFNs with the receptor complex induces activation
of signal transducer and activator of transcription (STAT)
family members, resulting in complex formations with
diﬀerent transcription factors [4]. IFN-γ shares similar but
distinct signal transduction pathways compared with that of
typeIIFNsandhasbiologicallydiﬀerentfunctionsfromtype
II F N s .
Type III IFNs, the newest IFN family, has been identiﬁed
as IFN-λ which includes 3 subtypes, IFN-λ1, -λ2a n d- λ3,
also known as interleukin-29 (IL-29), IL-28A, and IL-28B,
respectively, [5, 6]. The receptor complexes have also been
identiﬁed, and the interaction between the ligand and the
receptors seems to activate identical signal transduction
pathways as do type I IFNs. Nevertheless, type III IFNs could
have diﬀerent functions from the type I IFNs since type
III IFNs bind a speciﬁc receptor complex with restricted
expression manners.2 Clinical and Developmental Immunology
2. Structureof TypeIIIIFNs and
the Receptor Complex
Type III IFNs are similar to IL-10 family cytokines in the
structure as well as the type I IFNs [5, 6]. Type III IFNs can
therebyrepresentapossibleevolutionarylinkagebetweenthe
typeIIFNsandtheIL-10family.AllthetypeIIIIFN genesare
clusteredonchromosome 19inhumanandconsist ofseveral
exons, whereas the type I IFNs are mapped on chromosome
9 with a single exon. Murine type III IFN genes have also
been indentiﬁed, mIFN-λ1, -λ2a n d- λ3, but the mIFN-λ1
gene has a stop codon, producing nonfunctional truncated
protein [7]. Interestingly, sequences of bird and zebra ﬁsh
IFNs suggest that type III IFNs may represent an ancestral
IFN prototype that gave rise to intron-less type I IFNs by
retroposition events and gene duplications [8–10].
All of the type III IFNs bind the same heterodimeric
receptor, consisting of a newly identiﬁed subunit, IL-28Rα,
andtheIL-10Rβ subunit.IL-10Rβ isasubunitofthereceptor
complex for IL-10 and the IL-10-related cytokines such as
IL-22 and IL-26 [11]. Similar to other class II cytokines
receptors, IL-28Rα seems to determine the ligand binding
speciﬁcity and recruit intracellular signaling molecules. IL-
28Rα is also alternatively spliced to produce 2 variants
receptors; one encodes a receptor with a 29-amino acids
deletion in the intracytoplasmic portion and the other
only encodes the ectodomain. Biological signiﬁcances of the
isoforms remain uncharacterized, but they could serve as a
dominant negative form to inhibit the ligand binding or the
signal transduction.
T h et y p eII F Nr e c e p t o r sa r ee x p r e s s e di nv i r t u a l l ya l l
the somatic cells. In contrast, IL-28Rα expression seems
to be restricted in a tissues-speciﬁc manner although IL-
10R is ubiquitously expressed. The IL-28Rα transcripts are
undetectable in several cell types such as ﬁbroblastic and
endothelial cells [12]. The limited expression of IL-28Rα is
also shown in tumor cells, and the restricted expression of
the receptor complex determines the repertoire of type III
IFNs responsiveness, which may generate distinct biological
f u n c t i o n sf r o mt y p eII F N s .T h eI L - 2 8 R α expression levels
are diﬀerent even among the same cell lineages as found
in melanoma cells [13], but it is uncertain that the levels
are correlated with the responsibility to type III IFNs.
Interestingly, the expression, which was evidenced in the
majority of human melanoma specimens, was not identiﬁed
in premalignant benign nevi specimens [13]. IL-28Rα can
be inducible as type I IFN receptors; peripheral blood
mononuclear cells negative for the IL-28Rα became positive
for the expression when treated with IL-4 and granulocyte-
macrophage colony-stimulating factor treatments [14].
3.SignalingPathways
Antiviral responses are one of the major functions of IFNs,
and the Toll-like receptors- (TLRs-) mediated pathways are
essential in sensing of pathogens. The receptors detect most
types of viruses by recognizing the nucleic acids and act
as prototypical receptors to activate innate immunity. In
particular, both TLR8 and TLR9 contribute to type I IFN
production. Almost all of the nucleated cells response to
viral infection and secrete type I IFNs, in which a number
of molecules are involved including retinoic acid inducible
gene-I (RIG-1) [15]. The same TLR8 and TLR9 activate type
III IFNs production, and the induction mechanisms seem
to be similar to those of type I IFNs [16]. Nevertheless,
stimulation by either RNA or DNA viruses was less potent to
producetypeIIIIFNscomparedwithtypeI[17].Inaddition,
type III IFNs expressions were further augmented by IFN-
α through their upregulated TLRs- and RIG-I-mediated
signaling pathways. In contrast, hepatitis C virus infection
induced rather IFN-λs but not IFN-α or IFN-β mRNA [18].
These data imply that type III IFNs cover the diﬀerent range
of virus infections from type I IFNs and can interact with
other cytokines for antiviral activities.
Intercellular signal cascade systems are shared between
type I and III IFNs (Figure 1). Both type IFNs activate Janus
tyrosinekinase-(JAK-)STATspathways.LigationoftheIFNs
with respective receptors results in rapid phosphorylation
and activation of the receptor-associated tyrosine kinase 2
(TYK2) and JAK1, which in turn induce phosphorylation
and activation of STAT1, STAT2, STAT3, and STAT5. These
activated STATs form hetero- or homodimeric structures,
which are subsequently translocated to nucleus and bind
to IFN-stimulated response elements (ISREs) in regulatory
regions of the IFN-stimulated genes (ISGs). ISG factor 3
(ISGF3) is a transcriptional complex, composed of phospho-
rylatedSTAT1andSTAT2,andIFN-regulatoryfactor-9(IRF-
9)andinitiatestranscriptionsofISGs.PhosphorylatedSTATs
complexes also bind the IFN-γ activation site (GAS) and
start transcriptions of ISGs. A possible diﬀerence between
type I and III IFNs could be prolonged activation of STAT1
and STAT2 by type III IFNs, which is accompanied by
de novo STATs protein synthesis and delayed degradation
[19]. The downstream signaling of type III IFNs itself is
indistinguishable from that of type I IFNs. A microarray
analysis demonstrated IFN-λ1 upregulated 60 genes, most
of which belong to ISGs group and are the same as
found in IFN-α stimulation [13]. For example, 2,5OAS
and myxovirus resistance protein (MxA), both of which
are involved in viral protection, are induced by type I
and type III IFNs and, likewise, expression levels of major
histocompatibility complex (MHC) class I molecules, being
favorable for antiviral immunity, are also upregulated in type
I and type III IFNs-treated cells. Several lines of studies
indicated that the induction levels were lower in type III
than in type I IFNs, which may be attributable to a possible
diﬀerence in the activation processes between the types.
These evidences also raise a question as to the biological
signiﬁcance of type III IFNs in host defense mechanisms.
IFN pathways have an alternative circuit besides the JAK-
STATs-mediated system. The phosphatidyl-inositol-3-kinase
(PI3K) and the p38 kinase pathways have a certain role
in the IFN-induced signal transduction. More importantly,
activationofthePI3Kpathwayisdependentoncelltypesand
the p38 kinase pathway can modulate type-I-IFN-dependent
responses. It is however currently unknown whether type III
IFNs can activate the PI3K and the p38 kinase pathways. A
recent study nevertheless showed that type III IFNs inducedClinical and Developmental Immunology 3
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Figure 1: Signaling pathways mediated by type I and type III IFNs.
Type I IFNs binding to the receptor complex induces JAK1 and
TYK2 activation and phosphorylation of STAT1 and STAT2. The
phosphorylated STAT1/STAT2 complex with IRF-9 forms ISGF3,
which binds ISRE and initiates a number of transcriptions. Type
I IFNs also activate STATs without forming ISGF3 and transactivate
IFN-inducible genes through GAS elements. Additionally, type I
IFNs activate the PI3K and p38 pathways to stimulate transcription
of relevant genes through a number of transcription factors such
as AP-1. Similarly, type III IFNs induce the JAK-STATs pathways;
however, it is currently unknown whether type III IFNs activate the
PI3K and p38 pathways.
the activation of the mitogen-activated protein (MAP) and
both the p38 and Jun N-terminal kinase-MAP kinases were
involved in the gene expression [20]. On the other hand,
ad i ﬀerent study with human melanoma cells implied that
type III IFNs did not activate AKT or extracellular signal-
regulated kinases [13] and a possible involvement of the
alternative pathways in type III IFNs signaling is thereby
controversial.
4. GrowthInhibitory Action
IFNs have a growth inhibitory action, which can represent
one of the antiviral actions in host defense mechanism
due to eliminating virally infected cells. Type I IFNs have
been well documented to suppress growth of tumor cells
through inducing apoptosis and cell cycle arrest. Procaspases
are cleaved by IFN-α and IFN-β to induce apoptotic cell
death, and Takaoka et al. showed that the type I IFNs
augmented expression levels of the p53 tumor suppressor
gene, which suggest a close linkage between the antiviral
function and the antitumor activity [21]. The p53 induction
level by type I IFNs was however relatively low, and we
believe that the induced p53 level will not activate apoptotic
pathways [22]. Moreover, p53-mutated tumor cells were
subjected to IFN-mediated apoptosis [23]; thereby, type-I-
IFNs-mediated apoptosis can be rather p53 independent.
Type III IFNs also induced apoptosis but it was observed in
only some of cell lines derived from the same lineage. For
example, esophageal carcinoma cells express the type III IFN
receptors, and treatments with type III IFNs upregulated the
MHC class I expression and produced antiviral molecules,
2,5OAS and MxA, in all the cells. Growth suppression by
type III IFNs was thus observed in a third of esophageal
carcinoma cells tested [24], suggesting the discrete pathways
between the antiproliferative action and the other activities.
A repertoire of type-I-IFNs-sensitive cells is the same as that
of type III IFNs as far as we tested with the 9 kinds of
esophageal carcinoma cells: type-I-IFNs-sensitive cells were
also susceptible to type III and vice versa. It is interesting to
knowwhethertypeIIIIFNsproducebettergrowthinhibitory
actions than type I IFNs. Maher et al. showed that type III
IFNs produced greater growth inhibitory eﬀects than IFN-
α in a human keratinocyte cell line [19]. Direct comparison
of the inhibitory ability between type I and type III IFNs is
however diﬃcult because the biological action per the IFN
protein amount cannot be fairly judged. These data suggest
that signal transductions involved in the growth inhibition
are distinct from those of other functions such as antiviral
activities but both type I and type III IFNs shared the same
pathways pertinent to the growth inhibition.
The antiproliferative activity of type III IFNs was dem-
onstrated in a certain type of tumors [25–27] and in non-
tumorous intestinal epithelial cells [17]. The scope of type
III IFNs sensitivity is primarily dependent on the receptor
expression as well as cell-type speciﬁcity as mentioned. The
antiproliferative action, when more potent to tumors than
to the normal counterparts, can be beneﬁcial for cancer
treatments. It is however relatively diﬃcult to compare
such preferential sensitivity with paired cell lines, normal
and tumorous cells of the same cell origin. In esophagus,
Het-1A, a nontumorous cell line immortalized with SV40
T antigen, is completely resistant to the type III IFNs-
mediated growth inhibition despite being positive for the
receptors. Some esophageal carcinoma cells however were
also insensitive, and the preferential tumor susceptibility
remains unknown in esophageal carcinoma. In addition,
both intestinal epithelial cells and colon carcinoma cells were
susceptible to type III IFNs [17]. Although no comparative
data between tumors and nontumorous cells were available,
the preferential inhibitory action to tumors may not be
well evidenced. On the other hand, type I IFNs may have
such propensity to induce cell death in tumors rather than
nontumorous cells. The preferential inhibition could be
linked with better proliferative activity of tumors compared
with the normal counterparts but no conclusive data are
currently available as to the preferential cytotoxicity to
tumors with type I and type III IFNs.
The growth inhibition with type I and type III IFNs
was directly evidenced by the decreased cell numbers as well
as colorimetric assays. The activity is linked with tyrosine
phosphorylation of IL-28Rα at residues of 343 and 517,
which leads to optimal activation of STAT2 [28]. We recently
demonstrated 2 modes of the growth inhibition, cell cycle
arrest at G1-phase and apoptosis [24] .T h ec e l lc y c l es t o p
was accompanied by augmented p21 expression and pRb4 Clinical and Developmental Immunology
dephosphorylation, which seem to be independent on p53
signaling pathways. The same biochemical changes were also
demonstrated with murine tumor cells [27]. IFN-λ1 induced
celldeathinsomeofesophagealcarcinomacellsbyactivating
sequential caspase cleavage cascades including both intrinsic
and extrinsic apoptotic pathways. We initially thought that
IFN-λ1 induced G1 arrest and subsequently apoptosis but
this was not the case. The choice of either G1 arrest or sub-
G1inductionwasdependentonthecelltypes.Asmentioned,
induction of G1-phase arrest or increased sub-G1 fractions
by apoptosis was not observed in all the carcinoma cells
tested. It is also interesting whether G1-arrested cells with
type III IFNs were subjected to the same G1 arrest with type
I IFNs. We found that type I IFNs did not induced such
G1 arrest in the cells, suggesting a possible discrete pathways
between type I and type-III-IFNs-mediated signaling. These
studies suggested that the same cell repertoire within the
i d e n t i c a ll i n e a g ew a ss u s c e p t i b l et ob o t ht y p eIa n dt y p eI I I
IFNs in the growth inhibitory action but the mechanisms
were dependent on the cell type speciﬁcity.
5.Effects on ImmuneSystems
T y p eII F N sh a v eaw i d er a n g eo fi m m u n es t i m u l a t o r y
activities, but the main action is to augment T helper type
1 (Th1) cell responses, enhancing expression of MHC class
I molecules and generating natural-killer- (NK-) cell- and
T-cell-mediated cytotoxicity. Type I IFNs thus function to
elevate both innate and adaptive immune responses. Type III
IFNs seem to support cell-mediated immunity by upregu-
lating the class I expression, but there has not been enough
evidence to demonstrate that type III IFNs activate directly
immune cells and induce production of Th1 cytokines. A
recentstudyshowedthatIFN-λ1diminished IL-13levelsand
elevated IFN-γ production; however, subsequent study sug-
gested that peripheral blood cells treated with IFN-λ1 rather
upregulated expression levels of IL-6, IL-8, and IL-10 but not
TNF-α or IL-1β, suggesting the role in Th2 diﬀerentiation
but not in inﬂammatory reactions [29]. IFN-λ1h o w e v e r
has not been demonstrated to increase antibody formation
despite augmented Th2 cytokine production. In addition,
IFN-λ1 also elevated transcription of the monokine induced
by IFN-γ(Mig) and the IFN-γ inducible protein-10 (IP-10)
genes and in peripheral blood cells [30]. These molecules
favor for antiangiogenesis, which consequently suppress
tumor growth. These data collectively imply that type III
IFNshavesimilarimmuneregulatoryactivitiesastypeIIFNs
but could have some distinct properties. Moreover, type III
IFNs activate STAT4 molecules which are not stimulated by
type I IFNs through their phosphorylation, implying that
type-III-IFN-mediated eﬀects to immune systems are not
identical to those with type I IFNs. Interestingly, Mennechet
and Uz´ e reported contradictory data that type-III-IFNs-
treated dendritic cells induced FOXP3-positive regulatory T
cells [14] although meticulous further studies are required
regarding the immune tolerance or the suppressive factions.
In in vivo settings, secretion of type III IFNs from
tumors achieved antitumor responses against the trans-
duced tumors. Numasaki et al. showed that local secretion
of mIFN-λ2 from murine tumors produced antitumors
responses which were mediated by neutrophils, NK and
CD8-positive T cells [31]. The study also showed that IFN-γ
but not IL-12, IL-17, or IL-23 was essential for the antitumor
responses. Sato et al. demonstrated that NK and perhaps
NKT cells played a crucial role in the antitumor eﬀects
with less signiﬁcant involvement of cytotoxic T cells [27]
although an in vitro assay showed that type III IFNs did not
augment NK activities [13]. These results were inconsistent
but suggest that type III IFNs induce immune responses,
initially innate and sequentially adaptive immunity against
tumors. In contrast, Lasfar et al. demonstrated intriguing
results with murine B16 melanoma expressing mIFN-λ2[ 7].
The growth of the transduced tumors was retarded, and
even loss of the tumorigenicity was observed; however, mice
that rejected the B16 tumors secreting mIFN-λ2 failed to
induce immunological memory responses, suggesting that
mIFN-λ2doesnotcontributetoadaptiveimmuneresponses.
Moreover, they did not notice enhanced NK activities.
These data suggest a possible mechanism by upregulated
Mig and IP-10, both of which suppress neoangiogenesis
within tumors. The mechanisms of cytotoxicity operating in
vivo are diﬀerent from that in in vitro studies, and several
reasons besides the direct growth inhibitory action can
explain the antitumor eﬀects by type III IFNs, augmentation
of MHC class I antigens expression which subsequently
enhances antigenicity of tumors, a possible induction of
Th1 type cytokines which increases antigen presenting and
favors generation of cytotoxic T cells, and antiangiogenesis.
These actions are also shared with type I IFNs and thereby
speciﬁc immunological signiﬁcance of type III IFNs remains
unknown.
6. Conclusions andProspects
Type III IFNs have multiple functions including antiviral,
immunomodulatory, and antiproliferative actions, and the
majority of the actions overlap with those of type I IFNs.
A restricted expression of the type III receptor complex
in contrast with an ubiquitous expression of type I IFNs
receptors however suggests diﬀerential functions of the
type III IFNs in in vivo settings. Several studies in fact
demonstratedthatdiﬀerentialactivitiesbetweentwotypesof
IFNs in certain experimental models such as responsiveness
to viral infections. Antitumor eﬀects produced by type III
IFNs may however not be diﬀerent from those by type I IFNs
except the tissues-dependent receptor distributions.
Feasible clinical applications of type III IFNs are deter-
mined by a number of factors including the biological
activity and the potency. The antitumor eﬀects in vivo of
type III IFNs in comparison with type I IFNs are not well
established, but the activities of type III IFNs seem to be less
potent than those of type I IFNs from the standpoint of the
MHC class I upregulation and the antiproliferative action
although contradictory results were reported [19]. The
restricted expression of type III IFNs receptors however can
be a clue for the clinical application in term of cell-mediated
delivery of type III IFNs to target tumors. Fibroblasts or
endothelial cells, negative for type III IFNs receptors, areClinical and Developmental Immunology 5
resistant to the IFNs-mediated apoptosis but can deliver
the IFNs to the target cells in the vicinity. Transduction of
such carrier cells with the IFN genes and injection of the
cells into type-III-IFNs-sensitive target tumors can generate
antitumor eﬀects by inducing apoptotic cell death. Cell-
mediated delivery of a soluble factor can be more beneﬁcial
than systemic administrations since local concentrations of
the factor are relatively maintained in the delivery system.
Continuous secretion of factors from the producing cells
can produce better therapeutic eﬀects and circumvent any
possible adverse eﬀects.
Recombinant type I IFNs have been tested for the
antitumor eﬀects against a variety of tumors in clinical
settings. The clinical studies however did not reveal any
signiﬁcant beneﬁts partly due to the toxicity in systemic
administrations. Any combinatory use with several types of
anticancer agents did not increase the eﬀects in most of
the trials [32]. Type III IFNs have not yet been investigated
for the clinical eﬃcacy, but the similarity of its intracellular
signal pathways with type I IFNs, despite several advantages
of type III IFNs, implies that type III IFNs may not be
dramatically better as an anticancer agent than type I IFNs.
We probably need a novel strategy to obtain clinical beneﬁts
with type III as well as type I IFNs, which includes a local
administration in the form of encapsulated protein particles
and perhaps viral and nonviral expression vector systems.
Much of preclinical studies and clinical trials with such a
novel delivery system will be a subject in future.
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